Juvenile Clinically Amyopathic Derematomyositis: A Case Report and Review of Literature
Iranian Journal of Child Neurology,
Vol. 13 No. 3 (2019),
1 Tir 2019
,
Page 113-120
https://doi.org/10.22037/ijcn.v13i3.21092
Abstract
Abstract
Juvenile clinically amyopathic dermatomyositis (juvenile CADM) is a rare rheumatologic disease in children defined as presence of the hallmark cutaneous features of dermatomyositis in absence of muscle involvement. In this article we report an Iranian teenage girl presented to rheumatology clinic of Mofid Children's Hospital with cutaneous complaints who was diagnosed with juvenile CADM. Finally, we provide a literature review of previous studies on juvenile CADM.
- juvenile clinically amyopathic dermatomyositis
- juvenile amyopathic dermatomyositis
- juvenile dermatomyositis sine myositis
- Dermatomyositis
How to Cite
References
Sontheimer, R.D., Dermatomyositis: an overview of recent progress with emphasis on dermatologic aspects. Dermatol Clin, 2002. 20(3): p. 387-408.
Gerami, P., et al., A systematic review of juvenile-onset clinically amyopathic dermatomyositis. Br J Dermatol, 2007. 157(4): p. 637-44.
Jorizzo, J.L., Dermatomyositis: practical aspects. Arch Dermatol, 2002. 138(1): p. 114-6.
el-Azhary, R.A. and S.Y. Pakzad, Amyopathic dermatomyositis: retrospective review of 37 cases. J Am Acad Dermatol, 2002. 46(4): p. 560-5.
Bendewald, M.J., et al., Incidence of dermatomyositis and clinically amyopathic dermatomyositis: a population-based study in Olmsted County, Minnesota. Arch Dermatol, 2010. 146(1): p. 26-30.
Shiari, R., et al., Amyopathic juvenile dermatomyositis: a case presentation. Joint Bone Spine, 2009. 76(6): p. 722-3.
Pearson, C.M., PATTERNS OF POLYMYOSITIS AND THEIR RESPONSES TO TREATMENT. Ann Intern Med, 1963. 59: p. 827-38.
Gerami, P., et al., A systematic review of adult-onset clinically amyopathic dermatomyositis (dermatomyositis sine myositis): a missing link within the spectrum of the idiopathic inflammatory myopathies. J Am Acad Dermatol, 2006. 54(4): p. 597-613.
Sato, S., Clinical Utility of Anti-CADM-140/Melanoma Differentiation-Associated Gene 5 Autoantibody Titers in Patients with Juvenile Dermatomyositis and Rapidly Progressive Interstitial Lung Disease. ACR(abstract), 2012.
Kobayashi, I., et al., Anti-melanoma differentiation-associated gene 5 antibody is a diagnostic and predictive marker for interstitial lung diseases associated with juvenile dermatomyositis. J Pediatr, 2011. 158(4): p. 675-7.
Hoshino, K., et al., Anti-MDA5 and anti-TIF1-gamma antibodies have clinical significance for patients with dermatomyositis. Rheumatology (Oxford), 2010. 49(9): p. 1726-33.
Gono, T., et al., Brief report: Association of HLA-DRB1*0101/*0405 with susceptibility to anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis in the Japanese population. Arthritis Rheum, 2012. 64(11): p. 3736-40.
Cao, H., T.N. Parikh, and J. Zheng, Amyopathic dermatomyositis or dermatomyositis-like skin disease: retrospective review of 16 cases with amyopathic dermatomyositis. Clin Rheumatol, 2009. 28(8): p. 979-84.
Abe, Y., et al., Juvenile amyopathic dermatomyositis complicated by progressive interstitial pneumonia. Pediatr Int, 2010. 52(1): p. 149-53.
Liu, B., et al., Juvenile hypomyopathic dermatomyositis initiating with acquired inflammatory Blaschko-linear dermatosis. Eur J Dermatol, 2014. 24(3): p. 395-6.
Poddighe, D., et al., A hyper-ferritinemia syndrome evolving in recurrent macrophage activation syndrome, as an onset of amyopathic juvenile dermatomyositis: a challenging clinical case in light of the current diagnostic criteria. Autoimmun Rev, 2014. 13(11): p. 1142-8.
Kobayashi, N., et al., Clinical and laboratory features of fatal rapidly progressive interstitial lung disease associated with juvenile dermatomyositis. Rheumatology (Oxford), 2015. 54(5): p. 784-91.
Muro, Y., et al., Disappearance of anti-MDA-5 autoantibodies in clinically amyopathic DM/interstitial lung disease during disease remission. Rheumatology (Oxford), 2012. 51(5): p. 800-4.
Kang, E.H., et al., Myositis autoantibodies in Korean patients with inflammatory myositis: anti-140-kDa polypeptide antibody is primarily associated with rapidly progressive interstitial lung disease independent of clinically amyopathic dermatomyositis. BMC Musculoskelet Disord, 2010. 11: p. 223.
Cao, H., et al., Clinical manifestations of dermatomyositis and clinically amyopathic dermatomyositis patients with positive expression of anti-melanoma differentiation-associated gene 5 antibody. Arthritis Care Res (Hoboken), 2012. 64(10): p. 1602-10.
Sato, S., et al., Autoantibodies to a 140-kd polypeptide, CADM-140, in Japanese patients with clinically amyopathic dermatomyositis. Arthritis Rheum, 2005. 52(5): p. 1571-6.
Sato, S., et al., RNA helicase encoded by melanoma differentiation-associated gene 5 is a major autoantigen in patients with clinically amyopathic dermatomyositis: Association with rapidly progressive interstitial lung disease. Arthritis Rheum, 2009. 60(7): p. 2193-200.
Gil, B., et al., Diagnosis and treatment of clinically amyopathic dermatomyositis (CADM): a case series and literature review. Clin Rheumatol, 2016. 35(8): p. 2125-30.
Sato, S., et al., Anti-CADM-140/MDA5 autoantibody titer correlates with disease activity and predicts disease outcome in patients with dermatomyositis and rapidly progressive interstitial lung disease. Mod Rheumatol, 2013. 23(3): p. 496-502.
Hamaguchi, Y., et al., Common and distinct clinical features in adult patients with anti-aminoacyl-tRNA synthetase antibodies: heterogeneity within the syndrome. PLoS One, 2013. 8(4): p. e60442.
Callander, J., et al., Treatment of Clinically Amyopathic Dermatomyositis in adults: A Systematic Review. Br J Dermatol, 2016.
Rockerbie, N.R., et al., Cutaneous changes of dermatomyositis precede muscle weakness. J Am Acad Dermatol, 1989. 20(4): p. 629-32.
Fisler, R.E., et al., Aggressive management of juvenile dermatomyositis results in improved outcome and decreased incidence of calcinosis. J Am Acad Dermatol, 2002. 47(4): p. 505-11.
Tabarki, B., et al., Childhood dermatomyositis: clinical course of 36 patients treated with low doses of corticosteroids. Eur J Paediatr Neurol, 1998. 2(4): p. 205-11.
Pachman, L.M., et al., Duration of illness is an important variable for untreated children with juvenile dermatomyositis. J Pediatr, 2006. 148(2): p. 247-53.
Sallum, A.M., et al., Risk factors associated with calcinosis of juvenile dermatomyositis. J Pediatr (Rio J), 2008. 84(1): p. 68-74.
Plamondon, S. and P.B. Dent, Juvenile amyopathic dermatomyositis: results of a case finding descriptive survey. J Rheumatol, 2000. 27(8): p. 2031-4.
Huber, A.M., et al., Medium- and long-term functional outcomes in a multicenter cohort of children with juvenile dermatomyositis. Arthritis Rheum, 2000. 43(3): p. 541-9.
Ang, G.C. and V.P. Werth, Combination antimalarials in the treatment of cutaneous dermatomyositis: a retrospective study. Arch Dermatol, 2005. 141(7): p. 855-9.
Olson, N.Y. and C.B. Lindsley, Adjunctive use of hydroxychloroquine in childhood dermatomyositis. J Rheumatol, 1989. 16(12): p. 1545-7.
Euwer, R.L. and R.D. Sontheimer, Amyopathic dermatomyositis (dermatomyositis sine myositis). Presentation of six new cases and review of the literature. J Am Acad Dermatol, 1991. 24(6 Pt 1): p. 959-66.
Cosnes, A., et al., Dermatomyositis without muscle weakness. Long-term follow-up of 12 patients without systemic corticosteroids. Arch Dermatol, 1995. 131(12): p. 1381-5.
Nellen, R.G., et al., Juvenile amyopathic dermatomyositis with concomitant heart disease. Int J Dermatol, 2007. 46 Suppl 3: p. 22-4.
Park, J.H., et al., Muscle abnormalities in juvenile dermatomyositis patients: P-31 magnetic resonance spectroscopy studies. Arthritis Rheum, 2000. 43(10): p. 2359-67.
Rosenbaum, M.L. and N.B. Silverberg, Amyopathic dermatomyositis associated with familial polyposis coli. Pediatr Dermatol, 2004. 21(1): p. 91-2.
Al-Mayouf, S., A. Al-Mazyed, and S. Bahabri, Efficacy of early treatment of severe juvenile dermatomyositis with intravenous methylprednisolone and methotrexate. Clin Rheumatol, 2000. 19(2): p. 138-41.
Stringer, E. and B.M. Feldman, Advances in the treatment of juvenile dermatomyositis. Curr Opin Rheumatol, 2006. 18(5): p. 503-6.
Walling, H.W., P. Gerami, and R.D. Sontheimer, Juvenile-onset clinically amyopathic dermatomyositis: an overview of recent progress in diagnosis and management. Paediatr Drugs, 2010. 12(1): p. 23-34.
- Abstract Viewed: 175 times